These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Bioequivalence studies of drugs prescribed mainly for women. McGilveray IJ J Popul Ther Clin Pharmacol; 2011; 18(3):e516-22. PubMed ID: 22113364 [TBL] [Abstract][Full Text] [Related]
7. The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule. Brucker MC; King TL J Midwifery Womens Health; 2017 May; 62(3):308-316. PubMed ID: 28556499 [TBL] [Abstract][Full Text] [Related]
8. FDA drug labeling for pregnancy and lactation drug safety monitoring systems. Greene MF Semin Perinatol; 2015 Nov; 39(7):520-3. PubMed ID: 26428020 [TBL] [Abstract][Full Text] [Related]
9. A Comparison of FDA and EMA Pregnancy and Lactation Labeling. Kappel D; Sahin L; Yao L; Thor S; Kweder S Clin Pharmacol Ther; 2023 Jun; 113(6):1251-1257. PubMed ID: 36645246 [TBL] [Abstract][Full Text] [Related]
10. Prescription medications for use in pregnancy-perspective from the US Food and Drug Administration. Wesley BD; Sewell CA; Chang CY; Hatfield KP; Nguyen CP Am J Obstet Gynecol; 2021 Jul; 225(1):21-32. PubMed ID: 34215352 [TBL] [Abstract][Full Text] [Related]
11. The drug development process and the pregnant woman. Frederiksen MC J Midwifery Womens Health; 2002; 47(6):422-5. PubMed ID: 12484663 [TBL] [Abstract][Full Text] [Related]
12. The Importance of Clinical Research in Pregnant Women to Inform Prescription Drug Labeling. Dinatale M; Roca C; Sahin L; Johnson T; Mulugeta LY; Fletcher EP; Yao L J Clin Pharmacol; 2020 Dec; 60 Suppl 2():S18-S25. PubMed ID: 33274508 [TBL] [Abstract][Full Text] [Related]
13. FDA mulls changes to bioequivalence standards. Traynor K Am J Health Syst Pharm; 2010 Jun; 67(11):864. PubMed ID: 20484205 [No Abstract] [Full Text] [Related]
14. Drug safety: Pregnancy rating classifications and controversies. Wilmer E; Chai S; Kroumpouzos G Clin Dermatol; 2016; 34(3):401-9. PubMed ID: 27265079 [TBL] [Abstract][Full Text] [Related]
15. Monitoring for teratogenic signals: pregnancy registries and surveillance methods. Howard TB; Tassinari MS; Feibus KB; Mathis LL Am J Med Genet C Semin Med Genet; 2011 Aug; 157C(3):209-14. PubMed ID: 21766431 [TBL] [Abstract][Full Text] [Related]
16. New drugs of 1998. Hussar DA J Am Pharm Assoc (Wash); 1999; 39(2):151-206; quiz 289-92. PubMed ID: 10079651 [TBL] [Abstract][Full Text] [Related]
17. Prescription of hazardous drugs during pregnancy. Malm H; Martikainen J; Klaukka T; Neuvonen PJ Drug Saf; 2004; 27(12):899-908. PubMed ID: 15366977 [TBL] [Abstract][Full Text] [Related]
18. The Influence of the Food and Drug Administration Pregnancy and Lactation Labeling Rule on Drug Information Resources. Harris JB; Holmes AP; Eiland LS Ann Pharmacother; 2021 Apr; 55(4):459-465. PubMed ID: 32885981 [TBL] [Abstract][Full Text] [Related]
19. Drugs in renal disease and pregnancy. Sarwar A Best Pract Res Clin Obstet Gynaecol; 2019 May; 57():106-119. PubMed ID: 31031053 [TBL] [Abstract][Full Text] [Related]
20. Categorizing the safety of medications during pregnancy and lactation. Howland RH J Psychosoc Nurs Ment Health Serv; 2009 Apr; 47(4):17-20. PubMed ID: 19437927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]